Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
EP3413875B1	CHOLESTYRAMINE PELLETS AND METHODS FOR PREPARATION THEREOF	The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.	1. Extruded pellets comprising at least 70% w/w cholestyramine and i. at least 7% w/w of a vinylpyrrolidone-based polymer; or ii. a combination of at least 6% w/w of a vinylpyrrolidone-based polymer and at least 2% w/w of an acrylate copolymer; or iii. a combination of at least 5% w/w of a vinylpyrrolidone-based polymer and at least 3% w/w of an acrylate copolymer; or iv. a combination of at least 6% w/w of a vinylpyrrolidone-based polymer, at least 1% w/w of an acrylate copolymer and at least 10% w/w microcrystalline cellulose; or v. a combination of at least 5% w/w of a vinylpyrrolidone-based polymer, at least 2% w/w of an acrylate copolymer and at least 20% w/w microcrystalline cellulose.	Albireo AB, 413 46 Göteborg, SE, 101076814 | ALBIREO AB	2020-01-29	2016-02-09
EP3389626B1	SUSTAINED RELEASE CYCLOSPORINE-LOADED MICROPARTICLES	A controlled release pharmaceutical formulation is provided, comprising cyclosporine-loaded microparticles of a bioresorbable polymer comprising poly(D, L-lactide), wherein the mean diameter of the microparticles is in the range 20 μm to 40 μm. Also provided are medical uses of the pharmaceutical formulation, in particular in the treatment of uveitis, a process for production of the pharmaceutical formulation and injectable dosage forms, including those formulated for intravitreal injection.	1. A controlled release pharmaceutical formulation comprising cyclosporine-loaded microparticles of a bioresorbable polymer comprising poly(D, L-lactide), wherein the mean diameter of the microparticles is in the range 20 μm to 40 μm, and wherein the formulation comprises said microparticles suspended in a liquid vehicle, which liquid vehicle has a viscosity of between 30 and 45 mPas as measured at 20°C using an A&D SV-1a vibro viscometer (A&D Instruments Ltd) according to the manufacturer's instructions, and wherein the formulation comprises a thixotropic agent selected from the group consisting of: hypromellose, hydroxyethyl cellulose, hydrophillically-modified hydroxyethyl cellulose, Xanthan Gum, Guar Gum, and Cetyl alcohol, and wherein the liquid formulation exhibits shear-thinning behaviour such that the viscosity decreases under shear strain.	Midatech Pharma (Wales) Limited, Cardiff, South Glamorgan CF24 0AA, GB, 101679427 | MIDATECH PHARMA WALES LTD	2020-01-29	2015-12-18
EP3365323B1	SALTS OF TETRACYCLINES	A tetracycline salt comprising a tetracycline and an organic acid wherein the organic acid is oxalic acid or maleic acid is provided. The tetracycline is preferably doxycycline, minocycline, sancycline, lymecycline, tetracycline or demeclocycline, and preferred salts include oxycycline maleate, minocycline oxalate, tetracycline oxalate, demeclocycline maleate, demeclocycline oxalate, sancycline maleate, lymecycline maleate, or lymecycline oxalate. A pharmaceutical formulation comprising a tetracycline salt according to the invention is also provided, as is a medical device having coated thereon a salt or pharmaceutical formulation according to the invention.A salt of the invention, or a formulation of the invention are also provided for use as medicaments, particularly for use in the treatment or prevention of an inflammation and/or an infection. There is also provided a method of preparing a tetracycline salt,	1. A tetracycline salt comprising a tetracycline and an organic acid, wherein the organic acid is oxalic acid or maleic acid and the tetracycline is doxycycline, minocycline, sancycline, lymecycline, or demeclocycline.	Hovione Scientia Limited, Ringaskiddy, Co., Cork, IE, 101530889 | HOVIONE SCIENTIA LTD	2020-01-01	2015-11-24

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		which method comprises reacting a tetracycline base with an excess of an organic acid in a solvent.				
EP3135321B1	ADJUNCT MATERIAL TO PROVIDE DRUG ELUTION FROM VESSELS	Adjunct material is provided that has multiple reservoirs formed therein and releasably carrying a plurality of vessels that each retain at least one medicant. An implantable adjunct has at least one bioabsorbable polymer configured to maintain the vessels within a reservoir. Disruption of the at least one bioabsorbable polymer allows release of the vessels from at least one of the reservoirs. A rate of the vessels' release can be controlled by a degradation rate of the at least one bioabsorbable polymer. The released vessels are, in turn, disrupted to thereby cause at least one medicant disposed therein to release and thus provide a desired effect on tissue in-growth.	1. A staple cartridge assembly for use with a surgical stapler, comprising: a cartridge body having a plurality of staple cavities, each staple cavity having a surgical staple disposed therein; a biocompatible adjunct material releasably retained on the cartridge body and configured to be delivered to tissue by deployment of the staples in the cartridge body, the adjunct material including a plurality of distinct reservoirs formed therein, and the adjunct material including at least one biocompatible polymer; and an effective amount of at least one medicant selected from the list consisting of hemostatic agents, pro-inflammatory medicants, metalloproteinase inhibitors, antiinflammatory agents and growth factors, the at least one medicant being disposed within a plurality of vessels disposed within at least one of the reservoirs, the at least one medicant being effective to affect tissue in-growth, wherein disruption of the at least one polymer is configured to allow release of the vessels from the at least one of the reservoirs. 2. An end effector for a surgical instrument, comprising: a first jaw having a cartridge body removably attached thereto, the cartridge body having on a tissue-facing surface thereof a plurality of staple cavities configured to seat staples therein; a second jaw having an anvil with a plurality of staple forming cavities formed on a tissue-facing surface thereof, wherein at least one of the first and second jaws is movable relative to the other; a biocompatible adjunct material releasably retained on at least one of the tissue-facing surfaces of the first and second jaws and configured to be delivered to tissue by deployment of the staples in the cartridge body, the adjunct material including a plurality of distinct reservoirs formed therein, and the adjunct material including at least one biocompatible polymer; and an effective amount of at least one medicant selected from the list consisting of hemostatic agents, pro-inflammatory medicants, metalloproteinase inhibitors, antiinflammatory agents and growth factors, the at least one medicant being disposed within a plurality of vessels disposed within at least one of the reservoirs, the at least one medicant being effective to affect tissue in-growth, wherein disruption of the at least one polymer is configured to allow release of the vessels from the at least one of the reservoirs.	Ethicon LLC, 00969 Guaynabo, PR, 101662397 | ETHICON LLC	2020-01-15	2015-08-31
EP3095440B1	ANTIGEN-SPECIFIC IMMUNOTHERAPY USING TOLERIZING LIPOSOMES	The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic	1. Pharmaceutical composition made of at least one preparation, wherein the preparation comprises: tolerogenic liposomes tailored for effective	PLS-Design GmbH, 20255 Hamburg, DE, 100200341 | PLS DESIGN GMBH	2020-01-15	2015-05-19

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		dendritic cells (DCs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of DCs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomestailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory T cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokinesat the site of antigen or allergen presentation.	phagocytosis and loaded with at least one maturation inhibitor of dendritic cells (DCs) selected from a) calcipotriol, b) glucocorticoids, and c) antisense oligonucleotides capable of gene silencing of different pro-inflammatory molecules including CD40, CD80, and CD86 and at least one antigen or allergen or peptide derived thereof selected from ovalbumin (OVA), methylated BSA (mBSA), or the myelin oligodendrocyte glycoprotein (MOG)-derived peptide 35-55 (MOG(35-55), at least one immune modulator of phagocytosis selected from the nucleotides ATP and UTP, wherein at least said liposomes are embedded in a matrix suitable for locally restricted sustained release of therapeutically effective doses of said liposomes selected from PLGA-PEG-PLGA triblock copolymers. 6. Method for manufacturing a pharmaceutical composition according to any of the claims 1 to 4, wherein the said components are mixed with each other in a therapeutically effective quantity and embedded into said matrix, and wherein, optionally, galenic compounds are additionally admixed to one or all of the preparations.			
EP3277278B1	COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT	The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.	1. A solid composition wherein the composition comprises: (a) between 50 % and 95 % by weight axelopran sulfate, (b) between 5 % and 50 % by weight polyvinyl alcohol, (c) between 0 % and 45 % by weight polyethylene glycol 3350, and (d) between 0 % and 10 % by weight ascorbic acid.	Theravance Biopharma R&D IP LLC, South San Francisco, CA 94080, US, 101473458 | THERAVANCE BIOPHARMA R&D IP LLC	2020-01-08	2015-04-02
EP3236963B1	METHOD OF TREATMENT	The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.	1. A sustained-delivery formulation of 1, 2-dihydro-3-cyano-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone (milrinone) or a pharmaceutically acceptable salt thereof; for use in treating heart failure with preserved ejection fraction (HFpEF); wherein the formulation permits delivery of milrinone in an amount to achieve steady state plasma levels effective to alleviate the symptoms of HFpEF; wherein delivery of milrinone is in the range of between 0.1 µg/kg body weight per minute to 20 µg/kg body weight per minute.	Cardiora Pty Ltd, Melbourne, Victoria 3000, AU, 101845768 | CARDIORA PTY LTD	2020-01-29	2014-12-22
EP3071215B1	COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION	In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases	1. A TGF-β ligand trap comprising a TGF-β ligand binding domain of a TGF-β type II receptor and an Fc domain of an immunoglobulin for use in a method of treating, preventing, or reducing the progression rate of pulmonary hypertension (PH) in a subject, wherein the method comprises administering a therapeutically effective amount of the TGF-β ligand trap to the subject.	The Brigham and Women's Hospital Inc., Boston, MA 02115, US, 100823043 | Acceleron Pharma Inc., Cambridge, MA 02139, US, 101355326 | BRIGHAM & WOMENS HOSPITAL INC | ACCELERON PHARMA INC	2020-01-08	2013-11-21

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.				
EP2983663B1	SUSTAINED RELEASE OF BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION	The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.	1. A non-therapeutic method of fat reduction comprising injecting a sustained release formulation of Compound # 1: into a fat deposit.	ALLERGAN INC., Irvine, CA 92612, US, 100074706 | ALLERGAN INC	2020-01-22	2013-04-12
EP2877156B1	CHONDROITIN COMPLEXES FOR TRANSCUTANEOUS ABSORPTION	The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.	1. Pharmaceutical and cosmeceutical compositions containing non-covalent complexes between non-sulphated chondroitin having molecular weight between 5 and 100 kDa determined by size-exclusion chromatography and an active ingredient selected from diclofenac or ketorolac. 4. Non-covalent complexes of non-sulphated chondroitin having molecular weight between 5 and 100 kDa determined by size-exclusion chromatography and diclofenac or ketorolac which are absorbed through the skin and the mucous membranes and behave as transdermal carriers and slow-release systems for active ingredients.	Altergon S.A., 6900 Lugano, CH, 101194462 | ALTERGON SA	2020-01-01	2012-07-27
EP2635677B1	MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF	Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.	1. A modified FIX polypeptide, comprising an amino acid replacement in an unmodified FIX polypeptide, wherein: the amino acid replacement is selected from among R318Y, R318E, R318F and R318W in a mature FIX polypeptide having a sequence set forth in SEQ ID NO:3, or the same replacement at a corresponding amino acid residue in an unmodified FIX polypeptide; corresponding amino acid residues are identified by alignment of the unmodified FIX polypeptide with the polypeptide of SEQ ID NO:3; the unmodified FIX polypeptide consists of a sequence of amino acids set forth in SEQ ID NOS: 2, 3, 20 or 325 or is unmodified FIXa, which consists of a light chain that consists of residues 1-145, and a heavy chain that consists of residues 181-415, of SEQ ID NO: 3; the modified FIX polypeptide consists of 1, 2, 3, 4, 5, 6, 7, 8, or 9 additional modification(s); modifications are amino acid replacements, additions or deletions, or any combination thereof; the modified FIXa form of the FIX polypeptide exhibits increased procoagulant activity compared to the unmodified FIXa form of the FIX polypeptide that does not contain the modification(s); and procoagulant activity is assessed in an assay that measures blood coagulant activity.	Catalyst Biosciences Inc., South San Francisco, CA 94080, US, 101769536 | CATALYST BIOSCIENCES INC	2020-01-01	2010-11-03

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
EP2632553B1	A SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG	Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.	1. A process for preparing multivesicular liposomal formulations, the process comprising: providing a first emulsion by mixing a first aqueous phase and a volatile water-immiscible solvent phase, said solvent phase comprising at least one amphipathic lipid and at least one neutral lipid; mixing and emulsifying said first emulsion and a second aqueous phase to provide a second emulsion, said second emulsion comprising a continuous aqueous phase; removing the volatile water-immiscible solvent from the second emulsion to form a composition of blank multivesicular liposomal particles; and remote loading one or more acidic non-steroidal anti-inflammatory drugs into said multivesicular liposomes, wherein a gradient of low pH outside the multivesicular liposomes to high pH inside the multivesicular liposomes is present to drive the one or more acidic non-steroidal anti-inflammatory drugs into the multivesicular liposomes; wherein the acidic non-steroidal anti-inflammatory drug is selected from the group consisting of diclofenac, piroxicam, meloxicam and ketorolac.	Pacira Pharmaceuticals Inc., San Diego, CA 92121, US, 101024319 | PACIRA PHARMACEUTICALS INC	2020-01-01	2010-10-28
EP2433640B1	Composition comprising SOD, lutein and zeaxanthin	The invention relates to a composition comprising an enzyme selected from the group comprising superoxide dismutase (SOD) and SOD mimics and the like, in association with lutein and at least one stereoisomer of zeaxanthin; the invention also includes a kit of parts comprising such composition, wherein the kit comprises a first part comprising the enzyme, and a second part comprising lutein and at least one zeaxanthin isomer ; according to the invention, the composition or the kit of part may be included in a functional food, a nutraceutical composition or a food or dietary supplement, a medicament or a pharmaceutical composition, or a veterinarian product; the invention also relates to a composition for use in treating, preventing or stabilizing a disease, condition or disorder of the eye associated to oxidative stress, comprising administering to a subject in need thereof a medicament or a pharmaceutical composition according to the invention.	1. A composition comprising superoxide dismutase (SOD) in association with lutein and at least one zeaxanthin isomer.	OmniVision GmbH, 82178 Puchheim, DE, 101825770 | OMNIVISION GMBH	2020-01-15	2010-09-24
EP2225410B1	PROCESS FOR PRODUCING CELLULOSIC SHAPED ARTICLES, CELLULOSIC SHAPED ARTICLES AND THE USE THEREOF	The invention relates to a process for producing cellulosic shaped articles with stabilized inclusions in microfine dispersion of nonpolar organic compounds and mixtures by the dry-wet extrusion process. The shaped articles produced in this way exhibit by comparison with unmodified cellulose fibres a substantially increased storage capacity for heat and/or nonpolar active substances. They are suitable in particular for use in textiles for clothing, industrial textiles, leisure, medicine and cosmetics.	1. Process for producing cellulosic shaped articles having inclusions of at least one nonpolar organic compound by the wet and dry extrusion process, characterized in that a1) an emulsion comprising at least one nonpolar organic compound in a solution of cellulose in a solvent is prepared and stabilized by addition of at least one hydrophobic agent which increases the viscosity of the nonpolar organic compound, wherein the solvent employed is an ionic liquid, or a2) for stabilization the emulsion is admixed with nanoscale sheetlike	Smartpolymer GmbH, 07407 Rudolstadt, DE, 101506475 | SMARTPOLYMER GMBH	2020-01-01	2007-11-14

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		The functional effect may in these connections relate to the physical effect of heat storage and/or to the uniform and finely meterable storage and release of nonpolar active substances and plant extracts from the interior of the fibres of the shaped articles. It is possible through a suitable choice of the nonpolar portion to produce by this process also fibres able to absorb liquid or gaseous nonpolar substances.	and/or elongate hydrophobized particles which surround the droplet-like inclusions of the nonpolar organic compound(s) and form a suspension and b) the cellulose is recrystallized to obtain shaped articles having a cellulose matrix in which the nonpolar organic compound(s) is/are dispersedly incorporated, wherein the cellulosic shaped articles are fibres and wherein the nanoscale sheetlike and/or elongate hydrophobized particles comprise modified phyllosilicates.			
EP2146696B1	GRANULAR MATERIAL FOR DOSAGE FORMS	A granular material which has a mean particle diameter of 150 to 800 micrometers; and an unsettled bulk density of 0.1 to 0.35 g/cm3 and/or a compactibility which results in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa; and wherein the main component of the granular material is a cellulose derivative or an alkylene oxide homo- or copolymer or a blend thereof is useful for preparing dosage forms with a controlled release profile.	1. A granular material having a mean particle diameter of 150 to 350 micrometers and a compactibility resulting in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa, at least 60 % of the granular material being a water-soluble hydroxypropyl methyl cellulose having a hydroxypropoxyl substitution of 4 to 12 percent and a methoxyl substitution of 19 to 30 percent, based on the total weight of the granular material, which is obtained by subjecting the cellulose derivative in powder form to a granulation step.	Dow Global Technologies LLC, Midland, MI 48674, US, 101225780 | DOW GLOBAL TECHNOLOGIES LLC	2020-01-22	2007-04-13
EP1948069B1	PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG ELUTING IMPLANTABLE MEDICAL DEVICE	A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.	1. A implantable medical device comprising a luminal surface and a coating, wherein the coating comprises one or more layers of a matrix, one or more pharmaceutical substances that inhibits smooth muscle cell migration and/or proliferation, and a ligand attached to said matrix and operably configured to capture circulating progenitor cells on the luminal surface of said device after implantation of said medical device into a patient, characterized in that said one or more layers of said matrix are one or more layers of a non-polymer matrix, in that the non-polymer matrix is formed of a porous material comprising nano-particles, and in that the one or more pharmaceutical substances is trapped within and/or between said particles.	ORBUSNEICH MEDICAL PTE. LTD, 079906 Singapore, SG, 101812957 | ORBUSNEICH MEDICAL PTE LTD	2020-01-22	2005-11-15